ClinicalTrialsFinder
RecruitingNCT05396612

Role of the Immune Environment in Response to Therapy in Breast Cancer

Sponsor

Abramson Cancer Center at Penn Medicine

Enrollment

300 participants

Start Date

Oct 3, 2022

Study Type

OBSERVATIONAL

Conditions

Breast CancerHER2-negative Breast CancerER Positive Breast CancerTNBC - Triple-Negative Breast Cancer

Summary

This is an observational case-control study of tissues collected from women with ER+HER2- breast cancers. The immune environments of these cancers will be compared to triple negative and HER2+ breast cancers. No randomization or changes to standard of care treatment will occur as part of the study.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is examining the immune environment within breast cancer tumors to understand how different types of immune activity affect how a tumor responds to treatment. Researchers will collect tissue samples during surgery. **You may be eligible if...** - You are a woman 18 years old or older - You have been diagnosed with non-metastatic (not spread) breast cancer - You are having surgery at the University of Pennsylvania Health System **You may NOT be eligible if...** - You are male - You are under 18 years old - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERCollection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.

Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.

Locations(1)

Abramson Cancer Center

Philadelphia, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05396612

Related Trials

Genomic Services Research Program

NCT025959571 location

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

NCT052833304 locations

A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)

NCT070671381 location

Social and Environmental Determinants of Breast Cancer Survivorship: the Black Breast Cancer Survivor's Intervention (BBCSI)

NCT068852031 location

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

NCT06103864316 locations